Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
XCMG, the world’s fifth largest construction equipment company, unveils the XE15R hydraulic intelligent excavator, its first fully remote-controlled excavator, signaling a new phase in XCMG’s intelligentization of its excavator series.
Without a cab, XE15R is the company’s smallest excavator at 1.35m in height and 1.08m in width. Nicknamed “Little Swan”, the machine is agile and flexible in challenging working conditions.
The newly developed XE15R features a wireless control function with a 100-meter range, and integrates mechanic, electronic and hydraulic control technology with a CAN bus interface design. Unmanned driving reduces labor intensity, particularly useful in severe operating environments, such as toxic conditions or extreme temperatures.
As an intelligent excavator, XE15R also features a self-learning function. It can save operating maneuvers and then replay them automatically on request, a breakthrough that further ensures security, agility and reliability in operation.
“Intelligentization is an inevitable choice as XCMG follows the path of new industrialization, and XE15R shows that we do what we say. Its design embodies our pursuit of efficiency and user friendliness.” said Wang Min, president of XCMG. The launching of XE15R expands XCMG’s product line, and improves its customers’ construction quality, providing them with a more human-friendly working environment and better project solutions.
To view the multimedia release please visit
http://www.multivu.com/players/English/7605551-xcmg-xe15r-remote-controlled-excavator/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Bacardi Limited, the largest privately held spirits company in the world, today announced the initial phase of its US$250 million dollar investment in Scotch whisky production has been completed. This investment is to meet growing demand for the premium portfolio of Dewar’s Scotch whiskies, which are among the top-selling, favorite and most awarded Scotches in the world.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bacardi/46020/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Today Concentrix Corporation, a wholly-owned subsidiary of SYNNEX Corporation (NYSE: SNX), announced the addition of 19 delivery locations, across 13 countries, completing the second phase of the acquisition of IBM's global customer care and industry process services business. With over 95% of the acquisition completed, Concentrix continues to advance its position as a leader in the customer care and industry process services market, with over 45,000 employees delivering high value services.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7146451-concentrix-completes-2nd-phase-of-ibm-customer-care-business-acquisition
A “strategy-to-execution gap” plaguing corporations around the globe could lead companies to lose 50 percent of their potential cumulative cash flow on new growth investments if not properly addressed, according to CEB (NYSE: CEB), the leading member-based advisory company. That is because most new growth strategies lose value during the implementation phase, with at least one-in-three strategic initiatives failing altogether.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7082252-ceb-executive-guidance-for-2015-closing-strategy-to-execution-gaps/
Two beautiful baby girls had their public debut today at The Children’s Hospital of Philadelphia: Allison June and Amelia Lee Tucker, formerly conjoined twins, separated at the Hospital on Nov. 7. The Hospital held a press conference this morning to highlight this new phase in the lives of both infants.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59552-children-s-hospital-of-philadelphia-tucker-conjoined-twins-separated
Carowinds is unveiling plans to bring a fresh and exciting Carolina coastal experience to guests with a historic waterpark expansion in 2016. The transformation is part of the park’s commitment to celebrate Carowinds’ heritage as the place where the Carolinas come together, creating an “aquatic playground” with thrilling new attractions, new amenities and a new coastal name - Carolina Harbor.
Carolina Harbor waterpark will be included with park admission and will offer guests relaxing moments of tranquility and refreshing thrills by the “shores”, plus delivers a best day ever guest experience. The addition is the latest phase in a $50 million plus multi-year expansion at Carowinds, an effort kicked off by building the world’s tallest and fastest giga coaster, Fury 325, as well as new park food offerings which are regionally relevant.
To view the multimedia release go to:
http://www.multivu.com/players/English/7477452-carowinds-carolina-harbor-waterpark/
As a founding voice in the world of holistic wellness, Canyon Ranch® has the wisdom and expertise of spending nearly 40 years helping its guests achieve well-being. Now, the life-enhancement brand that’s built a devoted global following, is finally going global itself.
Under the guidance of the brand’s new Chief Executive Officer, Susan E. Docherty, the Company announced today the development of its first-ever international destination, Canyon Ranch Wellness Resort at Kaplankaya, on a spectacular peninsula of the sun-kissed Aegean coast. The initial phase of the Canyon Ranch development, which will open in July 2016, will include a strikingly modern resort and luxury real estate offerings. The property will integrate the signature wellness and lifestyle programming that has earned Canyon Ranch a famously loyal clientele worldwide.
To view the multimedia release go to:
http://www.multivu.com/players/English/7634751-canyon-ranch-resort-kaplankaya-turkey/
After analyzing millions of Internet visits and interviewing scores of consumers, Brookdale Senior Living has built a new website based on fresh insights into what’s most important to families searching for senior care. The first phase, which is a $4 million investment, went live on brookdale.com mid-August.
“With Brookdale’s website attracting more than 500,000 visits every month, it’s imperative to make it as useful to consumers as possible,” said David Cygan, Brookdale’s senior vice president of marketing. “As the nation’s largest senior living provider, we know our website is a primary source of information, with many people coming to us first as they embark on this journey,” Cygan said. “It’s important that we offer substantive resources that make it easier to find help in evaluating senior care options.” More than 80 percent of adult children turn to the Internet when they look for care for an aging parent, according to the company’s research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7722159-new-brookdale-senior-living-website/
Saxo Bank, the online trading and investment specialist, today releases their Q3 outlook that views Europe as insolvent, in a phase of denial of the actual problems and without a credible path forward. The Bank’s analysts also predict that growth in China will decrease to 6.5 percent, marking the next quarter as the low point for China and for world growth in general.
For the current crisis, Saxo Bank operates with a three-phase model that includes; Denial (which prompts policy-makers and central bankers to rely on quantitative easing and financial stimulus); Protest (where the public votes new governments which still fail to address the real problems) and; Mandate for Change (which forces policy-makers to take real action). According to the Bank, the EU has remained embedded in the first and second phases, having yet to arrive at a mandate for change.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/saxobank/56575/
